Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease
在美国不同种族和民族背景的参与者中，Lecanemab 和 Elenbecestat 治疗早期阿尔茨海默病的 2 期和 3 期安慰剂对照、双盲、随机试验的入组率
期刊:Annals of Neurology
影响因子:7.7
doi:10.1002/ana.26819
Grill, Joshua D; Flournoy, Charlene; Dhadda, Shobha; Ernstrom, Karin; Sperling, Reisa; Molina-Henry, Doris; Tranotti, Kate; Harris, Russell; Kanekiyo, Michio; Gee, Michelle; Irizarry, Michael; Kramer, Lynn; Aisen, Paul; Raman, Rema
